Disease or Syndrome – Page 18

BioNTech and BMS Announce First Global Data for PD-L1xVEGF Bispecific in Small Cell Lung Cancer, Set Phase 3 Dose

2 months ago talkbio0Tagged BioNTech, BNT327, Burning Mouth Syndrome, Myers, Overall response rate, PD-L1, PD-L1xVEGF, Pharmacotherapy, pumitamig, Small cell carcinoma of lung, squibb, Vascular Endothelial Growth Factor A

BioNTech; Bristol Myers Squibb; BMS; PD-L1xVEGF bispecific; BNT327; pumitamig; small cell lung cancer; SCLC; phase 2 trial; phase 3 dose; overall response rate; VEGF-A; PD-L1; chemotherapy

Takeda’s Phase 3 Success Positions Oveporexton (TAK-861) as Potential First Mover in Multibillion-Dollar Narcolepsy Market

2 months ago talkbio0Tagged Clinical Trials, multibillion-dollar market, Narcolepsy type 1, oveporexton, Phase 3, Standard of Care, TAK-861, Takeda, TPRG1L gene

Takeda; Phase 3; narcolepsy type 1; oveporexton; TAK-861; orexin agonist; multibillion-dollar market; clinical trial results; first mover; standard of care

Rapport Reveals Promising Phase 2a Data for RAP-219 Epilepsy Pill, Plans Phase 3 Trials

2 months ago talkbio0Tagged anti-seizure medication, Clinical Development, drug-resistant epilepsy, Epilepsy, focal onset seizures, RAP-219, Rapport Therapeutics, Seizures

Rapport Therapeutics; RAP-219; epilepsy; seizure reduction; Phase 2a clinical trial; focal onset seizures; Phase 3 trials; anti-seizure medication; drug-resistant epilepsy; clinical development

Junshi Biosciences Announces Phase 3 Win for IL-17A Drug JS005 in Psoriasis, Prepares China NDA Submission

2 months ago talkbio0Tagged Biosciences, China, clinical endpoints, Drug Approval, IL-17A monoclonal antibody, JS005, Junshi, Psoriasis

Junshi Biosciences; JS005; IL-17A monoclonal antibody; psoriasis; phase 3 trial; clinical endpoints; China drug approval

IQVIA Laboratories Bioinformatics Solutions Accelerate Genomic Insights for Drug Discovery in Partnership with NVIDIA

2 months ago talkbio0Tagged AI agents, Artificial Intelligence, Bio-Informatics, Drug Discovery, Enterprise, Genome, Genomics, IQVIA, NVIDIA, Precision Medicine

IQVIA; Genomic Insights; Bioinformatics; Drug Discovery; NVIDIA; AI Agents; Genomics; Precision Medicine; AI Enterprise; E360 Genomics

RFK Jr. Blasts Pharma Industry and Spreads mRNA Vaccine Misinformation During Heated Senate Hearing

2 months ago talkbio0Tagged Centers for Disease Control and Prevention (U.S.), COVID19 (disease), Leadership, mRNA misinformation, Pharma Industry, Policy, public health medicine (field), RFK Jr., Senate hearing, Vaccines

RFK Jr.; Senate hearing; pharma industry; mRNA misinformation; COVID-19 vaccines; public health; vaccine policy; CDC leadership

MRM Health Nets $64M and Treeline Gathers $200M: Fierce Biotech Fundraising Tracker 2025

2 months ago talkbio0Tagged Biocodex, Biotech Fundraising, Inflammatory Bowel Diseases, LBP, Live Biotherapeutic Product, Microbiome therapeutics, MRM Health, Series B funding, Treeline, Ulcerative Colitis

MRM Health; Series B Funding; Microbiome therapeutics; Ulcerative colitis; Live Biotherapeutic Product (LBP); Biocodex; Treeline; Biotech fundraising; IBD therapy

Enveda Raises $150M Series D, Advances Nature-Inspired Drug Programs

2 months ago talkbio0Tagged Biosciences, Dermatitis, Atopic, Enveda, Immune System Diseases, Investments, Mikael, nature-inspired drug discovery, Series D

Enveda Biosciences; Series D funding; $150 million; nature-inspired drug discovery; atopic dermatitis; immune diseases; Mikael Dolsten; biotech investment